Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II)
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Toxicity
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of giving chemotherapy together with biological therapy and to see how well they work in treating patients with stage II or stage III breast cancer.
详细描述
OBJECTIVES:
- Determine the toxic effects of sequential paclitaxel (or other taxane), doxorubicin, and cyclophosphamide followed by immunotherapy with activated T cells, interleukin-2, and sargramostim (GM-CSF) in patients with high-risk stage II or III breast cancer.
- Determine the disease-free survival and overall survival of patients treated with this regimen.
- Determine the immune function of patients treated with this regimen.
OUTLINE: Patients are stratified according to number of positive lymph nodes (less than 4 nodes vs 4-9 nodes vs 10 or more nodes), type of taxane chemotherapy during study (paclitaxel vs other taxane), and prior treatment with 2 of 3 study chemotherapy agents (yes vs no).
Patients receive doxorubicin IV on day 1 and filgrastim (G-CSF) on days 3-10 of 3 consecutive 14-day courses. Patients then receive paclitaxel or another taxane IV on day 1 and G-CSF on days 3-10 of 3 consecutive 14-day courses. Patients then receive cyclophosphamide IV on day 1 and G-CSF on days 3-10 of 3 consecutive 14-day courses. Patients who enroll after previously receiving 2 of these 3 chemotherapy drugs may receive the third. Treatment continues in the absence of disease progression or unacceptable toxicity.
After recovery from chemotherapy, patients undergo peripheral blood mononuclear cell (PBMC) collection. The PBMC are treated ex vivo with monoclonal antibody OKT3 to form activated T cells (ATC). The ATC are expanded for up to 14 days in interleukin-2 (IL-2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed stage II or III adenocarcinoma of the breast
- •High-risk disease
- •At least 4 positive lymph nodes
- •Fewer than 4 positive lymph nodes considered high-risk if one of the following is present:
- •HER2/neu-positive disease
- •Enlarged axillary nodes
- •Extra capsular extension of tumor from lymph node
- •Dermal lymphatic invasion
- •Vascular invasion
- •Bilateral disease
- •Familial breast cancer
- •T4 locally advanced disease
- •Clinically chemosensitive to prior paclitaxel (or other taxane), doxorubicin, and cyclophosphamide
- •No relapse after chemotherapy
- •No clinical evidence of brain metastases
- •Hormone receptor status:
- •Estrogen and progesterone receptor status known
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Menopausal status:
- •Not specified
- •Performance status:
- •Karnofsky 70-100% OR
- •Life expectancy:
- •At least 3 months
- •Hematopoietic:
- •Granulocyte count at least 1,500/mm^3
- •Platelet count at least 50,000/mm^3
- •Hemoglobin greater than 8 g/dL
- •Bilirubin less than 1.5 times normal
- •SGOT less than 1.5 times normal
- •Creatinine less than 1.8 mg/dL
- •Creatinine clearance at least 60 mL/min
- •BUN less than 1.5 times normal
- •Cardiovascular:
- •Ejection fraction at least 45% by MUGA
- •No uncontrolled or significant cardiovascular disease
- •No myocardial infarction within the past year
- •No significant congestive heart failure
- •FEV_1 at least 60% predicted
- •DLCO at least 60% predicted
- •FVC at least 60% predicted
- •No other malignancy except curatively treated squamous cell carcinoma in situ of the cervix or basal cell skin cancer
- •No other serious medical or psychiatric illness that would preclude study participation
- •HIV negative
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- 另有 13 项未显示
排除标准
- 未提供
结局指标
主要结局
Toxicity
Overall survival
Immune functions
Disease-free survival
次要结局
未报告次要终点